Zhitong Finance App News, Hengrui Pharmaceutical (01276) announced that recently, the company received a notice from the State Drug Administration to approve the addition of two additional indications for the Class 1 innovative drug, haitripopa ethanolamine tablets independently developed by the company.

Hetripopa ethanolamine tablets have been approved for marketing for three indications: 1. This product is suitable for adult patients with chronic primary immune thrombocytopenia (ITP) who have previously had poor response to treatment with glucocorticoids, immunoglobulins, etc. 2. This product is suitable for adult patients with severe aplastic anemia (SAA) who are not effective against immunosuppressive therapy (IST). 3. Combined immunosuppressive therapy is suitable for patients aged 15 and above who are treated for severe aplastic anemia (SAA).

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.